Logo

American Heart Association

  21
  0


Final ID: Sa4038

Atrial Fibrillation in Genotyped Dilated Cardiomyopathy: Epidemiology and Associated Risk Factors - Insights from the SHaRe Consortium

Abstract Body (Do not enter title and authors here): Background: Atrial fibrillation (AF) is the most common arrhythmia in dilated cardiomyopathy (DCM) and is associated with adverse outcomes. Characterization of AF in DCM by genotype and clinical features remains limited.

Aims: To describe AF prevalence and incidence in DCM stratified by genotype and disease gene, and to identify clinical and genetic predictors of incident AF.

Methods: Using the multicenter Sarcomeric Human Cardiomyopathy Registry (SHaRe), we included 3117 DCM patients who had genetic testing. AF prevalence, incidence, clinical characteristics and genotype (genotype-positive [G+], defined by the presence of a pathogenic/likely pathogenic [P/LP] variant in a DCM gene or genotype-negative [G-]) were assessed and further stratified by disease gene. Predictors of incident AF were identified with uni- and multivariable analyses. Covariates for the multivariable model were selected based on clinical relevance and discriminative performance (C-index 0.74), and included age at first site visit, sex, genotype, prior heart failure (HF) hospitalization and left atrial (LA) diameter.

Results: Of 3117 patients with DCM (mean age 48±15 years, 39% female, 35% G+), 12.3% (n=384) had prevalent AF. Among 2491 patients without prevalent AF, 12.5% (n=312) developed incident AF during a median follow-up of 4.5 years (IQR 1.6-9.0). AF burden varied by disease gene (Figure 1). Patients with P/LP LMNA variants had the highest AF prevalence (56.7%) and incidence (7.6/100 patient-years), with AF typically preceding left ventricular systolic dysfunction, and LMNA was the only gene independently associated with incident AF in multivariable analysis (HR 7.10, 95% CI 4.44-11.36; p<0.001). In contrast, those with P/LP TTN variants had lower AF burden (prevalence 24.4%, incidence 2.1/100 patient-years), comparable to G- patients, despite having the largest LA diameter (41±7mm). Patients with P/LP DSP variants were the 3rd largest gene group (n=156) but had the lowest AF prevalence (7.4%) and incidence (0.8/100 patient-years). Additional independent predictors of incident AF included male sex, prior HF hospitalization, older age at first visit, and larger LA diameter (Table 1).

Conclusion: In this multicenter cohort study of genotyped patients with DCM, LMNA had the strongest genetic association with AF, while TTN had lower AF rates despite larger LA diameter. Genotype-based risk stratification may help guide AF surveillance and management in DCM patients.
  • Heymans, Astrid  ( Cardiovascular Research Institute Maastricht, Maastricht University , Maastricht , Netherlands )
  • Reza, Nosheen  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Helms, Adam  ( UNIVERSITY OF MICHIGAN , Ann Arbor , Michigan , United States )
  • Shore, Supriya  ( UNIVERSITY OF MICHIGAN , Ann Arbor , Michigan , United States )
  • Prasad, Sanjay  ( ROYAL BROMPTON HOSPITAL , London , United Kingdom )
  • Tayal, Upasana  ( Royal Brompton Hospital , London , United Kingdom )
  • Wheeler, Matthew  ( Stanford University , San Francisco , California , United States )
  • Fornaro, Alessandra  ( AOU Careggi , Firenze , Italy )
  • Olivotto, Iacopo  ( University of Florence , Florence , Italy )
  • Mestroni, Luisa  ( University of Colorado Asnchutz , Aurora , Colorado , United States )
  • Wilsbacher, Lisa  ( NORTHWESTERN UNIVERSITY , Evanston , Illinois , United States )
  • Balakrishnan, Iswaree  ( The National Heart Centre, Singapor , Singapore , Singapore )
  • Khan, Sadiya  ( Northwestern University , Oak Park , Illinois , United States )
  • Sinagra, Gianfranco  ( Cardiovascular Department, Ospedali Riuniti and University , Trieste , Italy )
  • Merlo, Marco  ( Cardiovascular Department, Ospedali Riuniti and University , Trieste , Italy )
  • Rossano, Joseph  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Lin, Kimberly  ( Childrens Hospital of Philadelphia , Swarthmore , Pennsylvania , United States )
  • Ho, Carolyn  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Heymans, Stephane  ( Maastricht University Medical Centr , Maastricht , Netherlands )
  • Parikh, Victoria  ( Stanford University , San Francisco , California , United States )
  • Verdonschot, Job  ( Maastricht University Medical Centr , Maastricht , Netherlands )
  • Lakdawala, Neal  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Claggett, Brian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Stroeks, Sophie  ( Cardiovascular Research Institute Maastricht, Maastricht University , Maastricht , Netherlands )
  • Stewart, Garrick  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Seidman, Christine  ( MGB and HARVARD MEDICAL SCHOOL , Boston , Massachusetts , United States )
  • Beelen, Nina  ( Cardiovascular Research Institute Maastricht, Maastricht University , Maastricht , Netherlands )
  • Owens, Anjali  ( University of Pennsylvania , Wallingford , Pennsylvania , United States )
  • Day, Sharlene  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Astrid Heymans: DO NOT have relevant financial relationships | Nosheen Reza: DO have relevant financial relationships ; Consultant:Zoll:Past (completed) ; Research Funding (PI or named investigator):Bristol Myers Squibb:Active (exists now) ; Advisor:Novo Nordisk:Past (completed) ; Advisor:Idorsia:Past (completed) ; Advisor:AstraZeneca:Past (completed) ; Advisor:Bristol Myers Squibb:Active (exists now) ; Advisor:American Regent:Past (completed) ; Advisor:Roche:Active (exists now) | Adam Helms: DO have relevant financial relationships ; Consultant:Lexeo:Active (exists now) ; Consultant:Cytokinetics:Past (completed) ; Consultant:Preload Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Tenaya:Active (exists now) | Supriya Shore: No Answer | Sanjay Prasad: No Answer | Upasana Tayal: DO NOT have relevant financial relationships | Matthew Wheeler: No Answer | alessandra fornaro: DO NOT have relevant financial relationships | iacopo olivotto: DO have relevant financial relationships ; Advisor:BMS:Active (exists now) ; Advisor:Shire Takeda:Past (completed) ; Advisor:Genzyme:Past (completed) ; Advisor:Bayer Askbio:Active (exists now) ; Advisor:Lexicon:Active (exists now) ; Advisor:Rocket Pharma:Active (exists now) ; Advisor:Edgewise:Active (exists now) ; Advisor:Lexeo:Active (exists now) ; Advisor:Tenaya:Active (exists now) ; Advisor:Chiesi:Active (exists now) ; Advisor:cytokinetics:Active (exists now) | Luisa Mestroni: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Researcher:Greenstone Bio:Active (exists now) ; Advisor:Alexion:Active (exists now) ; Advisor:Rocket Biopharma:Active (exists now) ; Advisor:Tenaya Therapeutics:Active (exists now) | Lisa Wilsbacher: DO NOT have relevant financial relationships | Iswaree Balakrishnan: DO NOT have relevant financial relationships | Sadiya Khan: DO NOT have relevant financial relationships | Gianfranco Sinagra: DO NOT have relevant financial relationships | Marco Merlo: No Answer | Joseph Rossano: DO have relevant financial relationships ; Consultant:AskBIo:Active (exists now) ; Consultant:CRI Biotech:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Astellas:Active (exists now) | Kimberly Lin: DO have relevant financial relationships ; Consultant:Cytokinetics:Active (exists now) | Carolyn Ho: DO have relevant financial relationships ; Consultant:Bristol Myers Squibb:Active (exists now) ; Researcher:Tenaya:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Research Funding (PI or named investigator):Biomarin:Past (completed) ; Research Funding (PI or named investigator):Lexicon:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now) ; Research Funding (PI or named investigator):Bristol Myers Squib:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Sanofi:Past (completed) ; Consultant:Biomarin:Past (completed) ; Consultant:Lexicon:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) | Stephane Heymans: No Answer | Victoria Parikh: DO have relevant financial relationships ; Consultant:Lexeo Therapeutics:Active (exists now) ; Consultant:Borealis:Active (exists now) ; Consultant:Nuevocor:Active (exists now) ; Advisor:Constantiam Biosciences:Active (exists now) ; Consultant:BioMarin:Active (exists now) | Job Verdonschot: No Answer | Neal Lakdawala: DO have relevant financial relationships ; Consultant:BMS:Active (exists now) ; Advisor:Neuvocore:Active (exists now) ; Consultant:Gemma:Active (exists now) ; Advisor:Kardigan:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:Pfizer:Past (completed) ; Consultant:Alexion:Active (exists now) | Brian Claggett: No Answer | Sophie Stroeks: No Answer | Garrick Stewart: No Answer | Christine Seidman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Merck, Board of Directors:Active (exists now) ; Advisor:Tenaya:Active (exists now) ; Advisor:Maze:Past (completed) | Nina Beelen: No Answer | Anjali Owens: DO have relevant financial relationships ; Consultant:Alexion:Active (exists now) ; Consultant:Stealth:Active (exists now) ; Consultant:Corvista:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Imbria:Active (exists now) ; Consultant:Edgewise:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:Avidity:Active (exists now) ; Consultant:BMS:Active (exists now) ; Consultant:Biomarin:Active (exists now) ; Consultant:Bayer:Active (exists now) | Sharlene Day: DO have relevant financial relationships ; Consultant:Lexicon Pharmaceuticals:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Consultant:Solid Biosciences:Active (exists now) ; Advisor:Cytokinetics:Active (exists now) ; Research Funding (PI or named investigator):Lexicon Pharmaceuticals:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Atrial Fibrillation: from mechanism of disease development through new therapeutic targets

Saturday, 11/08/2025 , 02:30PM - 03:30PM

Abstract Poster Board Session

More abstracts on this topic:
A Nationwide Italian Network for the Clinical and Genetic Diagnosis of Familial Dyslipidemias: The LIPIGEN registry

Casula Manuela, Galimberti Federica, Olmastroni Elena, Arca Marcello, Averna Maurizio, Catapano Alberico

A Beta Tubulin Mutation Suppresses Arrhythmias and Improves Connexin 43 Localization in Heart of Duchenne Muscular Dystrophy Mice

Zhou Delong, Liu Tong, Yehia Ghassan, Romanienko Peter, Rodney George, Wehrens Xander, Lampe Paul, Gourdie Robert, Xie Lai-hua, Fraidenraich Diego, Nouet Julie, Mesa Elam, Yegneshwaran Vasisht, Geukgeuzian Geovanni, Adibemma Ifeanyichukwu, Nandakumar Swetha, Ramirez Edwin, Li Hong

More abstracts from these authors:
Social Determinants of Health and Outcomes in Patients with Hypertrophic Cardiomyopathy in the Sarcomeric Human Cardiomyopathy Registry (SHaRe)

Hafeez Neha, Lakdawala Neal, Ingles Jodie, Olivotto Iacopo, Ho Carolyn, Taylor Matthew, Khan Sadiya, Day Sharlene, Claggett Brian, Owens Anjali, Helms Adam, Saberi Sara, Lampert Rachel, Stendahl John, Ashley Euan, Parikh Victoria

The Impact of Genotype in Dilated and Arrhythmogenic Cardiomyopathy: Insights from the SHaRE Registry

Padalia Kishan, Khan Sadiya, Lakdawala Neal, Olivotto Iacopo, Owens Anjali, Prasad Sanjay, Axelsson Anna, Reza Nosheen, Shore Supriya, Sinagra Gianfranco, Tayal Upasana, Slaven Sarah, Verdonschot Job, Wheeler Matthew, Taylor Matthew, Merlo Marco, Fornaro Alessandra, Parikh Victoria, Wilsbacher Lisa, Mestroni Luisa, Medo Kristen, Graw Sharon, Claggett Brian, Bundgaard Henning, Helms Adam, Heymans Stephane, Ho Carolyn

You have to be authorized to contact abstract author. Please, Login
Not Available